Lv32
286 积分 2023-12-20 加入
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
3天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells
6天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
6天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
6天前
已完结
Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy
9天前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
14天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
14天前
已完结
Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C
15天前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
1个月前
已完结
Targeting KRAS in cancer
1个月前
已完结
皖公网安备34019202002308
